ES2193406T3 - Composiciones y metodos para mejorar la funcion intestinal. - Google Patents

Composiciones y metodos para mejorar la funcion intestinal.

Info

Publication number
ES2193406T3
ES2193406T3 ES97946986T ES97946986T ES2193406T3 ES 2193406 T3 ES2193406 T3 ES 2193406T3 ES 97946986 T ES97946986 T ES 97946986T ES 97946986 T ES97946986 T ES 97946986T ES 2193406 T3 ES2193406 T3 ES 2193406T3
Authority
ES
Spain
Prior art keywords
compositions
methods
lpg
intestinal function
improve intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97946986T
Other languages
English (en)
Inventor
Daniel J Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of ES2193406T3 publication Critical patent/ES2193406T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL GLP - 2 ESTIMULA EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL INTESTINO GRUESO, CUANDO SE ADMINISTRA JUNTO CON OTROS AGENTES. LA INVENCION PROPORCIONA COMPOSICIONES FARMACEUTICAS DE GLP - 2 CON AL MENOS OTRO AGENTE QUE AUMENTE LA ACTIVIDAD BIOLOGICA DEL GLP - 2, PROCEDIMIENTOS PARA FOMENTAR EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL GRUESO, Y PARA MEJORAR LOS TRASTORNOS NUTRICIONALES O GASTROINTESTINALES, GRACIAS A UN AUMENTO DE LOS NIVELES SERICOS DE GLP - 2 Y AL MENOS OTRO AGENTE, DESCRIBIENDOSE TAMBIEN KITS PARA LLEVAR A LA PRACTICA LOS PROCEDIMIENTOS DE LA INVENCION.
ES97946986T 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal. Expired - Lifetime ES2193406T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/763,177 US5952301A (en) 1996-12-10 1996-12-10 Compositions and methods for enhancing intestinal function

Publications (1)

Publication Number Publication Date
ES2193406T3 true ES2193406T3 (es) 2003-11-01

Family

ID=25067085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97946986T Expired - Lifetime ES2193406T3 (es) 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal.

Country Status (10)

Country Link
US (1) US5952301A (es)
EP (1) EP0944396B1 (es)
AT (1) ATE233096T1 (es)
AU (1) AU5220098A (es)
CA (1) CA2274596C (es)
DE (1) DE69719360T2 (es)
DK (1) DK0944396T3 (es)
ES (1) ES2193406T3 (es)
PT (1) PT944396E (es)
WO (1) WO1998025644A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) * 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
WO2001032199A1 (en) 1999-11-05 2001-05-10 Rogoff Joseph A Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
EP2769715A3 (en) * 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US7411039B2 (en) * 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20080269311A1 (en) * 2004-07-14 2008-10-30 Edwin Bernard Villhauer Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US20110295151A1 (en) * 2010-05-26 2011-12-01 Bakos Gregory J Enteroendocrine Manipulation for Metabolic Effect
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
EP4219534A3 (en) 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders
US20180200301A1 (en) * 2015-05-21 2018-07-19 Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
CN106589110B (zh) * 2015-10-15 2020-01-17 上海迈迹生物医药科技有限公司 包含聚合物和glp-2衍生物的缀合物
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607278B1 (en) * 1991-10-07 2002-04-17 The Brigham And Women's Hospital, Inc. Method for enhancing gut absorption
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP2275438A1 (en) * 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs

Also Published As

Publication number Publication date
CA2274596A1 (en) 1998-06-18
CA2274596C (en) 2004-11-09
DE69719360T2 (de) 2003-12-04
DE69719360D1 (de) 2003-04-03
ATE233096T1 (de) 2003-03-15
DK0944396T3 (da) 2003-06-23
AU5220098A (en) 1998-07-03
EP0944396A1 (en) 1999-09-29
US5952301A (en) 1999-09-14
WO1998025644A1 (en) 1998-06-18
EP0944396B1 (en) 2003-02-26
PT944396E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
BR9910251A (pt) Estimulação hematopoiética
AR039133A2 (es) Canula
ES2188652T3 (es) Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
DK124091A (da) Farmaceutisk genprodukt
ES8802184A1 (es) Procedimiento para la produccion de un mutante de activador de plasminogeno de tejido (t-pa) humano.
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
ES2183186T3 (es) Composiciones cosmeticas en polvo que contienen elastomeros de silicona.
ES2035847T3 (es) Un procedimiento para la elaboracion de una preparacion farmaceutica.
AR011357A1 (es) Estructura absorbente interlabial que calza en el espacio intervulvar
GEP20022804B (en) Erythropoietin Derivatives
ES2183486T3 (es) Formulaciones de fsh y de variantes de fsh que comprenden alcohol bencilico como agente preservativo.
ES2109818T3 (es) Agente para aumentar la conservacion de cuerpos de animales sacrificados.
BR0008787A (pt) Sistema à base de colágeno injetável para aplicação de células ou agentes terapêuticos
PT998287E (pt) Utilizacao de levobupivacaina
ES2088860T3 (es) Activador plasminogenico de tipo tisular humano modificado y su preparacion.
BRPI0418157A (pt) terapêutica de tumores alogênicos
ES2000871A6 (es) Un procedimiento para producir un copolimero de bloques selectivamente hidrogenado y fuoncionalizado
ES2086436T3 (es) Nuevos eteres y tioeteres de piperidilo inhibidores de la biosintesis de colesterol.
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
ES2151517T3 (es) Efectos de filamentos de actina sobre la estructura y lisis de coagulos de fibrina.
DE69625918D1 (de) Lang wirksames mittel zur rektalen verabreichung
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug